VivoSeq
Neurology

Japanese Encephalitis

25

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Japanese encephalitis is an emerging landscape with 25 programs across 7 companies. The most active players are Roche, GSK, Sanofi. 3 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2GSK logo

GSK

3 programs

Phase 3Sanofi logo

Sanofi

15 programs

Phase 3Novartis logo

Novartis

5 programs

Phase 3L

Liaoning Chengda Biotechnology CO., LTD

3 programs

ApprovedM

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Vaccine

25 of 29 classified programs — the dominant modality here.

14%ALL OTHERSSmall molecule310%Monoclonal antibody13%

Vaccine leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 100% of 50 pipeline programs.

Analysis

Trial Status

50

clinical trials

Completed43 · 86%
Unknown status5 · 10%
Active, not recruiting1 · 2%
Recruiting1 · 2%

Clinical Trials

Trial Activity

50 trials

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
Recruiting·SSK Bioscience Co., Ltd.·Phase 1/2·NCT06680128·402 enrolled
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
Active, not recruiting·LLiaoning Chengda Biotechnology CO., LTD·Phase 4·NCT06825312·600 enrolled
Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
Completed·Sanofi logoSanofi·Phase 3·NCT00735644·1,200 enrolled
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Completed·Novartis logoNovartis·Phase 3·NCT01662440·661 enrolled
Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children
Completed·MMahidol University·Phase 3·NCT01408537·152 enrolled
Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population
Completed·VValneva Austria GmbH·Phase 3·NCT01041573·1,869 enrolled
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
Completed·LLiaoning Chengda Biotechnology CO., LTD·Phase 4·NCT06331702·408 enrolled
Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
Completed·VValneva Austria GmbH·Phase 3·NCT00595270·349 enrolled
Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
Completed·VValneva Austria GmbH·Phase 3·NCT00595790·374 enrolled
Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
Completed·PPATH·Phase 4·NCT00463684·278 enrolled
Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
Completed·PPATH·Phase 4·NCT00463476·305 enrolled
Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®)
Completed·Sanofi logoSanofi·Phase 2·NCT00982137·108 enrolled
Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine
Completed·MMedical University of Vienna·Phase 4·NCT01398540·60 enrolled
Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine
Completed·PPATH·Phase 3·NCT00412516·519 enrolled
Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
Completed·VValneva Austria GmbH·N/A·NCT00596102·3,258 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)